Trial of Neoadjuvant Trastuzumab Emtansine in Patients With HER2-Equivocal Breast Cancer
Status:
Withdrawn
Trial end date:
2019-05-01
Target enrollment:
Participant gender:
Summary
This is an open label, neoadjuvant phase II study to evaluate the objective response,
toxicity, and safety of trastuzumab emtansine in patients with newly diagnosed HER2-equivocal
breast cancer. Trastuzumab emtansine at a dose of 3.6 mg/kg will be intravenously
administered every 3 weeks for a total of 6 weeks. Patients who achieve a partial or complete
response after the 6-week treatment (responders) will continue on trastuzumab emtansine for
an additional 12 weeks.
Phase:
Phase 2
Details
Lead Sponsor:
Jenny C. Chang, MD
Collaborators:
Genentech, Inc. The Methodist Hospital Research Institute The Methodist Hospital System